GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures
Plug Pulled After Three Trial Flops
Executive Summary
Bintrafusp alfa was once seen as a blockbuster contender by the partners but GSK’s withdrawal narrows further its chances of success.
You may also be interested in...
Merck KGaA Cancer Deal-Making Spree Continues With PDS Tie-Up
PDS is getting rights to Merck's M9241, a tumor-targeting interleukin-12 fusion compound which is a key component, together with its own investigational HPV16-targeted immunotherapy, in a triple combination being studied to treat advanced HPV-positive cancers.
Merck KGaA Health Care Head Happy With Old And New Mix
The German firm’s pharma chief Peter Guenter says that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.
Merck KGaA Healthcare Head Happy With Old And New Mix
The German firm’s pharma chief Peter Guenter tells Scrip that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.